APEX-002-A01-02 will evaluate the safety and efficacy of APEX-52 low dose, multi-dose synthetic psilocybin drug product in treating depression in Veterans with PTSD VANCOUVER, BC, Nov. 1, 2022 /CNW/ – Apex Labs Ltd. (“APEX” or the “Company”), a pharmaceutical company optimizing the standard of mental health care for Veterans, is pleased to announce its approval for the first North American take…


Previous articleLusaris Therapeutics Launches with $60 Million Series A Financing to Redefine the Treatment of Severe Neuropsychiatric and Neurological Disorders
Next articleFree Webinar – NueLife: Empowering Patients with At-Home Ketamine Therapy